Intrinsic Therapeutics Stock

Develops therapies to treat disc herniations in the spine for discectomy patients

Sign up today and learn more about Intrinsic Therapeutics Stock

Invest in or value your shares in one or many pre-IPO companies through an EquityZen investment vehicle.

About Intrinsic Therapeutics Stock

Intrinsic Therapeutics is a medical device company that develops therapies for treating disc herniations in the spine for discectomy patients. It offers Barricaid anular prosthesis that allows the direct reconstruction of weakened and ruptured annulus and soft tissues of the spine. The company also offers spinal implants to treat the causes of sciatica and low back pain. It serves surgeons and patients. The company was formerly known as Intrinsic Orthopedics and changed its name to Intrinsic Therapeutics in January 2003. Intrinsic Therapeutics was founded in 2000 and is based in Woburn, Massachusetts.

Funding History

January 2001$7.2M
December 2002$25.0M
September 2007$21.0M
February 2010$18.0M
November 2012$11.6M
September 2014$17.3M
December 2016$17.9M
May 2017$28.0M
May 2017$21.0M
April 2019$52.0M


Vice President, Global Sales

Remco Maljers


David Neafus

Founder & Executive Director

Gregory Lambrecht

Vice President, Global Marketing

Ivo Scheepens

President and CEO

Cary Hagan

Chief Operating Officer

Jacob Einhorn


EquityZen does not have an affiliation with, formal relationship with, or endorsement from any companies featured above. This profile is based on publicly available information and is intended to be informative in nature.

Some data provided by Crunchbase

Join 630,000+ Investors and Shareholders

On our trusted digital marketplace for private companies

EquityZen Recognized As: